Minerva Neurosciences, Inc. (NERV)
Chart Events
Performance Outlook
| Previous Close | 3.6000 |
| Open | 3.7400 |
| Bid | 3.3400 x 800 |
| Ask | 3.3600 x 1000 |
| Day's Range | 3.3050 - 3.7400 |
| 52 Week Range | 2.5100 - 17.0400 |
| Volume | |
| Avg. Volume | 688,357 |
| Market Cap | 142.754M |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8410 |
| Earnings Date | Mar 07, 2022 - Mar 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.33 |
- GlobeNewswire
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2022. Roluperidone Update Following the March 2, 2022 Type C Meeting with th
- Simply Wall St.
Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2022. Roluperidone Update On April 7, 2022, the Company issued a press release pr
